NCT05607095 trial: what clinicians have said so far
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
- NCT05607095 ↗
- Recruiting
- Memorial Sloan Kettering Cancer Center
- Focused size, estimated: 1–150 verified statements once built
Discussed at: 2026 ASCO Annual Meeting, ESMO Congress 2026
We haven't built an HCP commentary report on NCT05607095 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05607095 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) for Patients With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Uveal Melanoma; Melanoma; Metastatic Uveal Melanoma; Metastatic Melanoma
- Interventions
- Lifileucel (LN-144/LN-145)
- Arms
- Participants with Metastatic Uveal Melanoma · Experimental
- Participants with Metastatic Sarcoma · Experimental
- Expansion Patients with angiosarcoma · Experimental
- Enrollment
- 40 (estimated)
- Primary outcomes
- Adverse events as evaluated by CTCAE v5.0
- Sponsor
- Memorial Sloan Kettering Cancer Center with Iovance Biotherapeutics, Inc.
- Start
- Nov 1, 2022
- Primary completion
- May 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05607095 · updated Sep 15, 2026